Regulus Therapeutics (RGLS) 5.55 $RGLS
Regulus Reports Positive Top-line Data
PR Newswire - Tue Jun 07, 6:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the primary endpoint analysis of one of the company's ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV). The study was designed to evaluate a shortened, four-week treatment regimen containing a subcutaneous administration of 2 mg/kg of RG-101 at Day 1 and Day 29, in combination with 4 weeks of once/daily approved anti-viral agents Harvoni®, Olysio®, or Daklinza(TM). The study enrolled 79 treatment naïve genotype 1 and 4 HCV patients (Harvoni® arm, n=27, Olysio® arm, n=27, Daklinza(TM) arm, n=25). The primary endpoint of the study is virologic response 12 weeks following conclusion of treatment.
RGLS: 5.55 (+0.10)
Biotech Industry's Stocks Get Research Review
ACCESSWIRE - Fri Jun 03, 8:17AM CDT
LONDON, UK / ACCESSWIRE / June 3, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Biotechnology industry. Companies recently under review include XOMA, Vericel, Cara Therapeutics, and Regulus Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
CARA: 4.89 (-0.07), VCEL: 2.23 (unch), RGLS: 5.55 (+0.10), XOMA: 0.55 (-0.01)
Regulus to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Fri Jun 03, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Paul Grint, M.D., President and Chief Executive Officer of Regulus, will present a company overview at the Jefferies 2016 Healthcare Conference on Friday, June 10, 2016 at 12:30 p.m. ET.
RGLS: 5.55 (+0.10)
Dr. Hugh Rosen Joins Regulus Board of Directors
PR Newswire - Thu Jun 02, 3:15PM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced Hugh Rosen, M.D., Ph.D. was elected to the Company's board of directors at its Annual Meeting of Stockholders held earlier today.
RGLS: 5.55 (+0.10)
Regulus Expands Clinical Trial Collaboration with GSK
PR Newswire - Wed Jun 01, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced that it has expanded its clinical trial collaboration agreement with GSK (NYSE: GSK) for the development of RG-101, Regulus' wholly-owned, GalNAc-conjugated anti-miR that targets miR-122. In the expanded collaboration, the companies plan to conduct a multi-centered, randomized, dose-ranging Phase II study evaluating the combination of RG-101 and GSK's long-acting parenteral ("LAP"
formulation of GSK2878175 as a potential single-visit cure in patients chronically infected with HCV. This study will be conducted outside the United States and is planned to begin in the fourth quarter of 2016. Based on predicted enrollment rates, interim results from this expanded collaboration should be available in the second half of 2017, enabling a potential initiation of a pivotal study in late 2017. As with the initial collaboration, both parties will share equally in the costs associated with the study. Neither Regulus nor GSK has any further obligations or commitments to each other beyond this expanded clinical collaboration agreement.
RGLS: 5.55 (+0.10), GSK: 42.72 (+0.96)
Regulus Appoints Allison Wey as Vice President, Investor Relations & Corporate Communications
PR Newswire - Mon May 23, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that Allison Wey has been appointed Vice President, Investor Relations and Corporate Communications. Ms. Wey brings over 25 years of experience in investor relations, corporate communications, media relations and investment banking.
RGLS: 5.55 (+0.10)
Regulus to Present New RG-012 Data at The 53rd European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress
PR Newswire - Fri May 20, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new data on RG-012, the company's anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy, is being presented in three posters during the 53rd European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress May 21-24 in Vienna, Austria.
RGLS: 5.55 (+0.10)
Regulus to Present at the 2016 UBS Global Healthcare Conference
PR Newswire - Wed May 18, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Paul Grint, M.D., President and Chief Executive Officer of Regulus, will present a company overview at the 2016 UBS Global Healthcare Conference on Wednesday, May 25, 2016 at 8:00 a.m. ET. The conference is being held at the Grand Hyatt Hotel in New York, NY.
RGLS: 5.55 (+0.10)
Regulus to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference
PR Newswire - Wed May 04, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Paul Grint, M.D., President and Chief Executive Officer of Regulus, will present a company overview at the Bank of America Merrill Lynch 2016 Healthcare Conference on Thursday, May 12, 2016 at 9:20 a.m. PDT. The conference is being held at the Encore at the Wynn Las Vegas.
RGLS: 5.55 (+0.10)
Regulus Reports First Quarter 2016 Financial Results and Recent Highlights
PR Newswire - Mon May 02, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the first quarter ended March 31, 2016 and provided a summary of recent corporate highlights.
RGLS: 5.55 (+0.10)
Regulus Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call
PR Newswire - Tue Apr 26, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended March 31, 2016 on Monday, May 2, 2016, after the U.S. financial markets close.
RGLS: 5.55 (+0.10)
Why Regulus Therapeutics Is Slumping 14% Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 15, 12:50PM CDT
IMAGE SOURCE:REGULUS THERAPEUTICS. What: Despite Regulus Therapeutics reporting interim trial data showing that its RG-101 can deliver high cure rates in hepatitis C patients, its shares sunk 14.2% at 1:00 p.m. ET today. So what: The...
JNJ: 117.02 (+0.56), GILD: 83.32 (+0.87), RGLS: 5.55 (+0.10), BMY: 73.14 (+0.83)
Regulus Presents Additional Interim Data on RG-101 at International Liver Congress(TM) (ILC 2016)
PR Newswire - Fri Apr 15, 2:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced additional interim results from one of the company's ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV) during an oral presentation at the International Liver Congress 2016 (ILC 2016) taking place April 13-17 in Barcelona, Spain. The study was designed to evaluate a shortened, four-week treatment regimen containing a subcutaneous administration of 2 mg/kg of RG-101 at Day 1 and Day 29, in combination with 4 weeks of once/daily approved anti-viral agents Harvoni®, Olysio®, or Daklinza(TM). The study enrolled 79 treatment naïve genotype 1 and 4 HCV patients (Harvoni® arm, n=27, Olysio® arm, n=27, Daklinza(TM) arm, n=25).
RGLS: 5.55 (+0.10)
Regulus to Present New RG-101 Data at The International Liver Congress(TM) 2016 (ILC 2016)
PR Newswire - Wed Mar 16, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new data on RG-101, the company's anti-miR-122 in Phase II development for the treatment of Hepatitis C Virus infection (HCV), will be presented as an oral presentation during the general session at The International Liver Congress(TM) (ILC) 2016, April 13-17 in Barcelona, Spain. Three poster presentations outlining additional RG-101 clinical and preclinical research will also be included as part of the meeting's poster sessions.
RGLS: 5.55 (+0.10)
Is This the Company Gilead Sciences Should Fear Most? (Hint: It's Not Merck or AbbVie)
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 20, 8:00AM CST
SOURCE: REGULUS THERAPEUTICS. Gilead Sciences is racking up billions of dollars in sales of its hepatitis C drugs every quarter, but competitors are angling for market share, and that has investors nervous that Gilead Sciences' revenue in the...
GILD: 83.32 (+0.87), MRK: 57.30 (+0.26), RGLS: 5.55 (+0.10), ABBV: 60.39 (+0.41), BMY: 73.14 (+0.83)
Regulus Completes RG-101 Enrollment in Phase II Combination Study
PR Newswire - Thu Jan 21, 7:00AM CST
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced key 2016 programmatic goals to advance RG-101, Regulus' wholly-owned therapy for the treatment of HCV. RG-101 is a GalNAc-conjugated anti-miR targeting miR-122, a host factor for HCV infection. Regulus' Phase II program and development strategy for RG-101 includes evaluating RG-101 in combination studies with different approved direct-acting anti-HCV agents (DAAs), in combination with an investigational oral DAA that can be formulated into a Long Acting Parenteral formulation for injection (LAP) providing the potential for a single-visit therapy, and in certain underserved HCV patient populations.
RGLS: 5.55 (+0.10)
Will Insiders Be Tempted To Buy More RGLS At The New 52-Week Low?
TheOnlineInvestor.com - Thu Jan 14, 12:08PM CST
In trading on Thursday, shares of Regulus Therapeutics Inc touched a new 52-week low of $5.80/share. That's a $15.42 share price drop, or -72.67% decline from the 52-week high of $21.22 set back on 03/05/2015.
RGLS: 5.55 (+0.10)
Biotechnology Stocks Technical Data -- Regulus Therapeutics, Progenics Pharma, Spectrum Pharma, and Sorrento Therapeutics
ACCESSWIRE - Tue Jan 12, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / January 12, 2016 / Park Lane Advisor has initiated coverage on the following equities: Regulus Therapeutics Inc. (NASDAQ: RGLS), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Sorrento Therapeutics Inc. (NASDAQ: SRNE). Free research report on Regulus Therapeutics can be accessed at http://www.parklaneadvisor.com/ On Monday, January 11, 2016, the NASDAQ Composite ended at 4,637.99, down 0.12%, the Dow Jones Industrial Average advanced 0.32%, to finish the day at 16,398.57, and the S&P 500 closed at 1,923.67, up 0.09%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PGNX: 4.66 (-0.02), SPPI: 6.80 (+0.08), RGLS: 5.55 (+0.10), SRNE: 5.71 (+0.03)
CORRECTING and REPLACING Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer
BusinessWire - Mon Jan 11, 9:19AM CST
Headline of release should read: Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer (instead of Rosetta Genomics Granted U.S. Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer). In addition, there is a change to the first paragraph, first sentence. "U.S. Patent" should read "European Patent."
ROSG: 1.25 (+0.07), RGLS: 5.55 (+0.10)
Rosetta Genomics Granted U.S. Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer
BusinessWire - Mon Jan 11, 8:11AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the U.S. Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 08844596.0, relating to "Targeting microRNAs for the Treatment of Liver Cancer." This patent is co-owned by Regulus Therapeutics, Inc. (Nasdaq:RGLS). The patent claims chemically-modified, anti-microRNA molecules for use in the treatment of liver cancer, including miR-21, miR-125a, miR-191, miR-210, miR-222, miR-378a, miR-423, and miR-638.
ROSG: 1.25 (+0.07), RGLS: 5.55 (+0.10)
Regulus Reports Positive Top-line Data
PR Newswire - Tue Jun 07, 6:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the primary endpoint analysis of one of the company's ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV). The study was designed to evaluate a shortened, four-week treatment regimen containing a subcutaneous administration of 2 mg/kg of RG-101 at Day 1 and Day 29, in combination with 4 weeks of once/daily approved anti-viral agents Harvoni®, Olysio®, or Daklinza(TM). The study enrolled 79 treatment naïve genotype 1 and 4 HCV patients (Harvoni® arm, n=27, Olysio® arm, n=27, Daklinza(TM) arm, n=25). The primary endpoint of the study is virologic response 12 weeks following conclusion of treatment.
RGLS: 5.55 (+0.10)
Biotech Industry's Stocks Get Research Review
ACCESSWIRE - Fri Jun 03, 8:17AM CDT
LONDON, UK / ACCESSWIRE / June 3, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Biotechnology industry. Companies recently under review include XOMA, Vericel, Cara Therapeutics, and Regulus Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
CARA: 4.89 (-0.07), VCEL: 2.23 (unch), RGLS: 5.55 (+0.10), XOMA: 0.55 (-0.01)
Regulus to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Fri Jun 03, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Paul Grint, M.D., President and Chief Executive Officer of Regulus, will present a company overview at the Jefferies 2016 Healthcare Conference on Friday, June 10, 2016 at 12:30 p.m. ET.
RGLS: 5.55 (+0.10)
Dr. Hugh Rosen Joins Regulus Board of Directors
PR Newswire - Thu Jun 02, 3:15PM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced Hugh Rosen, M.D., Ph.D. was elected to the Company's board of directors at its Annual Meeting of Stockholders held earlier today.
RGLS: 5.55 (+0.10)
Regulus Expands Clinical Trial Collaboration with GSK
PR Newswire - Wed Jun 01, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced that it has expanded its clinical trial collaboration agreement with GSK (NYSE: GSK) for the development of RG-101, Regulus' wholly-owned, GalNAc-conjugated anti-miR that targets miR-122. In the expanded collaboration, the companies plan to conduct a multi-centered, randomized, dose-ranging Phase II study evaluating the combination of RG-101 and GSK's long-acting parenteral ("LAP"
formulation of GSK2878175 as a potential single-visit cure in patients chronically infected with HCV. This study will be conducted outside the United States and is planned to begin in the fourth quarter of 2016. Based on predicted enrollment rates, interim results from this expanded collaboration should be available in the second half of 2017, enabling a potential initiation of a pivotal study in late 2017. As with the initial collaboration, both parties will share equally in the costs associated with the study. Neither Regulus nor GSK has any further obligations or commitments to each other beyond this expanded clinical collaboration agreement. RGLS: 5.55 (+0.10), GSK: 42.72 (+0.96)
Regulus Appoints Allison Wey as Vice President, Investor Relations & Corporate Communications
PR Newswire - Mon May 23, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that Allison Wey has been appointed Vice President, Investor Relations and Corporate Communications. Ms. Wey brings over 25 years of experience in investor relations, corporate communications, media relations and investment banking.
RGLS: 5.55 (+0.10)
Regulus to Present New RG-012 Data at The 53rd European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress
PR Newswire - Fri May 20, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new data on RG-012, the company's anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy, is being presented in three posters during the 53rd European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress May 21-24 in Vienna, Austria.
RGLS: 5.55 (+0.10)
Regulus to Present at the 2016 UBS Global Healthcare Conference
PR Newswire - Wed May 18, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Paul Grint, M.D., President and Chief Executive Officer of Regulus, will present a company overview at the 2016 UBS Global Healthcare Conference on Wednesday, May 25, 2016 at 8:00 a.m. ET. The conference is being held at the Grand Hyatt Hotel in New York, NY.
RGLS: 5.55 (+0.10)
Regulus to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference
PR Newswire - Wed May 04, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Paul Grint, M.D., President and Chief Executive Officer of Regulus, will present a company overview at the Bank of America Merrill Lynch 2016 Healthcare Conference on Thursday, May 12, 2016 at 9:20 a.m. PDT. The conference is being held at the Encore at the Wynn Las Vegas.
RGLS: 5.55 (+0.10)
Regulus Reports First Quarter 2016 Financial Results and Recent Highlights
PR Newswire - Mon May 02, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the first quarter ended March 31, 2016 and provided a summary of recent corporate highlights.
RGLS: 5.55 (+0.10)
Regulus Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call
PR Newswire - Tue Apr 26, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended March 31, 2016 on Monday, May 2, 2016, after the U.S. financial markets close.
RGLS: 5.55 (+0.10)
Why Regulus Therapeutics Is Slumping 14% Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 15, 12:50PM CDT
IMAGE SOURCE:REGULUS THERAPEUTICS. What: Despite Regulus Therapeutics reporting interim trial data showing that its RG-101 can deliver high cure rates in hepatitis C patients, its shares sunk 14.2% at 1:00 p.m. ET today. So what: The...
JNJ: 117.02 (+0.56), GILD: 83.32 (+0.87), RGLS: 5.55 (+0.10), BMY: 73.14 (+0.83)
Regulus Presents Additional Interim Data on RG-101 at International Liver Congress(TM) (ILC 2016)
PR Newswire - Fri Apr 15, 2:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced additional interim results from one of the company's ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV) during an oral presentation at the International Liver Congress 2016 (ILC 2016) taking place April 13-17 in Barcelona, Spain. The study was designed to evaluate a shortened, four-week treatment regimen containing a subcutaneous administration of 2 mg/kg of RG-101 at Day 1 and Day 29, in combination with 4 weeks of once/daily approved anti-viral agents Harvoni®, Olysio®, or Daklinza(TM). The study enrolled 79 treatment naïve genotype 1 and 4 HCV patients (Harvoni® arm, n=27, Olysio® arm, n=27, Daklinza(TM) arm, n=25).
RGLS: 5.55 (+0.10)
Regulus to Present New RG-101 Data at The International Liver Congress(TM) 2016 (ILC 2016)
PR Newswire - Wed Mar 16, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new data on RG-101, the company's anti-miR-122 in Phase II development for the treatment of Hepatitis C Virus infection (HCV), will be presented as an oral presentation during the general session at The International Liver Congress(TM) (ILC) 2016, April 13-17 in Barcelona, Spain. Three poster presentations outlining additional RG-101 clinical and preclinical research will also be included as part of the meeting's poster sessions.
RGLS: 5.55 (+0.10)
Is This the Company Gilead Sciences Should Fear Most? (Hint: It's Not Merck or AbbVie)
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 20, 8:00AM CST
SOURCE: REGULUS THERAPEUTICS. Gilead Sciences is racking up billions of dollars in sales of its hepatitis C drugs every quarter, but competitors are angling for market share, and that has investors nervous that Gilead Sciences' revenue in the...
GILD: 83.32 (+0.87), MRK: 57.30 (+0.26), RGLS: 5.55 (+0.10), ABBV: 60.39 (+0.41), BMY: 73.14 (+0.83)
Regulus Completes RG-101 Enrollment in Phase II Combination Study
PR Newswire - Thu Jan 21, 7:00AM CST
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced key 2016 programmatic goals to advance RG-101, Regulus' wholly-owned therapy for the treatment of HCV. RG-101 is a GalNAc-conjugated anti-miR targeting miR-122, a host factor for HCV infection. Regulus' Phase II program and development strategy for RG-101 includes evaluating RG-101 in combination studies with different approved direct-acting anti-HCV agents (DAAs), in combination with an investigational oral DAA that can be formulated into a Long Acting Parenteral formulation for injection (LAP) providing the potential for a single-visit therapy, and in certain underserved HCV patient populations.
RGLS: 5.55 (+0.10)
Will Insiders Be Tempted To Buy More RGLS At The New 52-Week Low?
TheOnlineInvestor.com - Thu Jan 14, 12:08PM CST
In trading on Thursday, shares of Regulus Therapeutics Inc touched a new 52-week low of $5.80/share. That's a $15.42 share price drop, or -72.67% decline from the 52-week high of $21.22 set back on 03/05/2015.
RGLS: 5.55 (+0.10)
Biotechnology Stocks Technical Data -- Regulus Therapeutics, Progenics Pharma, Spectrum Pharma, and Sorrento Therapeutics
ACCESSWIRE - Tue Jan 12, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / January 12, 2016 / Park Lane Advisor has initiated coverage on the following equities: Regulus Therapeutics Inc. (NASDAQ: RGLS), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Sorrento Therapeutics Inc. (NASDAQ: SRNE). Free research report on Regulus Therapeutics can be accessed at http://www.parklaneadvisor.com/ On Monday, January 11, 2016, the NASDAQ Composite ended at 4,637.99, down 0.12%, the Dow Jones Industrial Average advanced 0.32%, to finish the day at 16,398.57, and the S&P 500 closed at 1,923.67, up 0.09%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PGNX: 4.66 (-0.02), SPPI: 6.80 (+0.08), RGLS: 5.55 (+0.10), SRNE: 5.71 (+0.03)
CORRECTING and REPLACING Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer
BusinessWire - Mon Jan 11, 9:19AM CST
Headline of release should read: Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer (instead of Rosetta Genomics Granted U.S. Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer). In addition, there is a change to the first paragraph, first sentence. "U.S. Patent" should read "European Patent."
ROSG: 1.25 (+0.07), RGLS: 5.55 (+0.10)
Rosetta Genomics Granted U.S. Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer
BusinessWire - Mon Jan 11, 8:11AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the U.S. Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 08844596.0, relating to "Targeting microRNAs for the Treatment of Liver Cancer." This patent is co-owned by Regulus Therapeutics, Inc. (Nasdaq:RGLS). The patent claims chemically-modified, anti-microRNA molecules for use in the treatment of liver cancer, including miR-21, miR-125a, miR-191, miR-210, miR-222, miR-378a, miR-423, and miR-638.
ROSG: 1.25 (+0.07), RGLS: 5.55 (+0.10)
